|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In the case of PRL gene, the highest expression was observed; PRL+ adenomas were in third place.
|
26884293 |
2016 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dysregulation of the signaling pathways that govern lactotrope biology contributes to tumorigenesis of prolactin (PRL)-secreting adenomas, or prolactinomas, leading to a state of pathological hyperprolactinemia.
|
25472533 |
2015 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PRL receptor (PRLR) gene expression was determined by microarrays on aldosterone-producing adenomas and normal adrenals and validated by real-time PCR.
|
26176803 |
2015 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactinomas, or prolactin-secreting adenomas, constitute the most common type of hyperfunctioning pituitary adenoma.
|
24135847 |
2014 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP mutation-positive patients have a characteristic clinical phenotype with usually young- or childhood-onset growth hormone (GH) and/or prolactin (PRL)-secreting adenomas and can be seen in cases with no apparent family history as well.
|
23652674 |
2013 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We propose to limit AIP testing to patients diagnosed before age 40 yr with apparently sporadic large pituitary adenomas, especially GH- or PRL-secreting adenomas.
|
22319033 |
2012 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
For BAG1 we confirm a significantly higher expression in functioning (both PRL and GH producing) adenomas than non-functioning ones, while LAPTM4B does not exhibit any expression changes between different classes of pituitary tumours.
|
23023342 |
2012 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Treatment with dopamine agonists in patients with prolactin (PRL) adenomas and Parkinson's disease is associated with central side effects.
|
22672924 |
2012 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Genome-wide changes were first determined in a discovery cohort comprising non-functioning (NF), growth hormone (GH), prolactin (PRL)-secreting and corticotroph (CT) adenoma relative to post-mortem pituitaries.
|
23045325 |
2012 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas.
|
23310926 |
2012 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Recently, our group found that 15-PGDH expression was low in prolactin (PRL) secreting adenomas (prolactinomas) and growth hormone (GH) secreting adenomas (GHomas) using fiber-optic BeadArray technology.
|
22580984 |
2012 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Because human epidermal growth factor receptor 2 (HER2)/ErbB2 is overexpressed in prolactinomas and ErbB receptor ligands regulate prolactin (PRL) gene expression, we tested the role of HER2/ErbB2 in prolactinoma hormone regulation and adenoma cell proliferation to assess the rationale for targeting this receptor for prolactinoma therapy.
|
21106881 |
2011 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A significantly higher content of CRABP1 mRNA was observed in NFPA compared to functioning adenomas, and PRL-secreting adenomas showed a lower expression of this gene compared to normal pituitary.
|
21270509 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Germline mutations in the aryl hydrocarbon receptor-interacting protein gene (AIP) predispose to young-onset pituitary tumours, most often to GH- or prolactin-secreting adenomas, and most of these patients belong to familial isolated pituitary adenoma families.
|
21454441 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Using quantitative real-time RT-PCR, we evaluated expression of 24 genes from the DLK1-MEG3 locus in 44 human pituitary adenomas (25 NFAs, 7 ACTH-secreting, 7 GH-secreting, and 5 PRL-secreting adenomas) and 10 normal pituitaries.
|
21871428 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In tissue microarray analysis, prominent expression of CXCR7 was observed in GH-producing adenomas and PRL-producing adenomas, and in macroadenomas (P < 0.05).
|
19302186 |
2009 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The functional differentiation of pituitary cells and adenomas follows the combination of transcription factors and co-factors in three cell lineages [growth hormone-prolactin-thyroid-stimulating hormone lineage, adrenocorticotrophic hormone (ACTH)/pro-opiomelanocortin (POMC) lineage, and follicular stimulating hormone (FSH)/luteinizing hormone (LH) lineage], which include Pit-1, GATA-2, SF-1, NeuroD1/beta2, Tpit, ERalpha, and others.
|
18228160 |
2008 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the present study, we evaluated the expression of NT and its receptors (NTR1, 2 and 3) in a series of 50 pituitary adenomas [11 growth hormone (GH)-, eight prolactin (PRL)-, four adrenocorticotrophic hormone (ACTH)- and 27 nonfunctioning adenomas].
|
18624930 |
2008 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The RT-PCR assay and electrophoresis of the PCR-products showed that p16(INK4A) mRNA was undetectable in: 62% of non-functioning, 8% of growth hormone-secreting, 17% of prolactin-secreting and 17% of adrenocorticotropin-secreting adenomas.
|
18058237 |
2008 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunostaining for SNAP-25 (streptavidin-biotin peroxidase complex method) showed that 10 PRL-producing adenomas were strongly immunoreactive.
|
18633321 |
2008 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These results are in agreement with previous studies in that prolactin-producing adenomas are component tumors in PAP.
|
17914118 |
2007 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment.
|
16328513 |
2006 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most prevalent form of pituitary tumors in humans.
|
16809921 |
2006 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
HGS and GUK1 were significantly over expressed in GH-secreting adenomas, compared with ACTH-secreting adenomas and nonfunctioning tumors, and with PRL-secreting adenomas, respectively.
|
16832584 |
2006 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
|
15994755 |
2005 |